Pharmafile Logo

icosapent ethyl

Bristol-Myers Squibb (BMS) building

Keytruda, Opdivo narrow Tecentriq’s lead in bladder cancer

BMS’ drug is currently under FDA and EMA review in advanced urothelial carcinoma

Eli Lilly HQ

Lilly snags first approval for sarcoma drug Lartruvo

Granted accelerated approval by the FDA becoming first front-line STS therapy for 40 years

Roche Basel Switzerland

Lung cancer OK for Tecentriq sets up showdown with Merck and BMS

Broad label will aid Roche’s PD-L1 inhibitor in head-to-head NSCLC market-share battle

- PMLiVE

FDA halts study of Teva and Regeneron’s pain drug fasinumab

Firms to redesign phase III trial excluding patients with advanced osteoarthritis after set back

Roche - Basel

Lucentis claims speedy FDA review for myopia complication

Roche’s drug achieved superior visual acuity gains compared to standard treatment in trials

- PMLiVE

Novartis’ Ilaris wins three new FDA approvals

Immunotherapeutic expands in rare Periodic Fever Syndrome conditions

Sanofi reception

Sanofi eyes March approval for dupilumab in atopic dermatitis

Analysts suggest sales could reach $2.8bn annually if licensed in eczema and asthma

- PMLiVE

Amgen claims first US go-ahead for Humira biosimilar

Amjevita receives FDA approval but faces patent infringement lawsuit from AbbVie

- PMLiVE

Sarepta soars as FDA clears its muscular dystrophy drug

Analysts anticipate blockbuster status for DMD therapy despite efficacy concerns

EISAI

Eisai wins EU licence for kidney cancer drug Kisplyx

Approved as a second-line combination treatment for advanced RCC

Sanofi reception

Sanofi trumpets new IGlarLixi data after regulatory delay

Reports that the combination drug is more effective at controlling glucose than Lantus alone

- PMLiVE

Newron back on track for Xadago approval in US

Italian firm is not required to conduct additional trials for its Parkinson’s disease drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links